INNATE PHARMA : IPH4102: Completion of the dose escalation part of the phase I trial – Data to be presented at ICML in June 2017 in Lugano

Innate Pharma SA (the “Company” – Euronext Paris: FR0010331421 – IPH) today announced that it has completed the dose escalation part of its ongoing Phase I trial evaluating IPH4102 in patients with relapsed/refractory cutaneous T cell lymphomas. No dose-limiting toxicity was reported and the maximum tolerated dose (MTD) was not reached.